BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 14716027)

  • 21. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
    Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
    Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
    Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
    Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of FLT3 in leukemia.
    Gilliland DG; Griffin JD
    Curr Opin Hematol; 2002 Jul; 9(4):274-81. PubMed ID: 12042700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
    Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
    Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
    Tickenbrock L; Müller-Tidow C; Berdel WE; Serve H
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):153-65. PubMed ID: 16503833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
    Nishioka C; Ikezoe T; Yang J; Takeshita A; Taniguchi A; Komatsu N; Togitani K; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Jun; 32(6):865-72. PubMed ID: 17983653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Normal and oncogenic FLT3.
    Naoe T; Kiyoi H
    Cell Mol Life Sci; 2004 Dec; 61(23):2932-8. PubMed ID: 15583855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
    Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
    Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
    Stone RM; DeAngelo DJ; Klimek V; Galinsky I; Estey E; Nimer SD; Grandin W; Lebwohl D; Wang Y; Cohen P; Fox EA; Neuberg D; Clark J; Gilliland DG; Griffin JD
    Blood; 2005 Jan; 105(1):54-60. PubMed ID: 15345597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications.
    Advani AS
    Curr Pharm Des; 2005; 11(26):3449-57. PubMed ID: 16250847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel FLT3 tyrosine kinase inhibitors.
    Levis M; Small D
    Expert Opin Investig Drugs; 2003 Dec; 12(12):1951-62. PubMed ID: 14640939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
    Drexler HG
    Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.
    Walters DK; Stoffregen EP; Heinrich MC; Deininger MW; Druker BJ
    Blood; 2005 Apr; 105(7):2952-4. PubMed ID: 15585651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
    Robinson LJ; Xue J; Corey SJ
    Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
    Stone RM; De Angelo J; Galinsky I; Estey E; Klimek V; Grandin W; Lebwohl D; Yap A; Cohen P; Fox E; Neuberg D; Clark J; Gilliland DG; Griffin JD
    Ann Hematol; 2004; 83 Suppl 1():S89-90. PubMed ID: 15124689
    [No Abstract]   [Full Text] [Related]  

  • 38. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
    Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
    Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
    Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.